Search company, investor...

Degron Therapeutics

Founded Year



Series A | Alive

Total Raised


Last Raised

$22M | 1 yr ago

About Degron Therapeutics

Degron Therapeutics focuses on new small-molecule drugs of molecular glue. Its products can be used in all therapeutic areas, benefiting human health and addressing unmet clinical medical needs. The company was founded in 2021 and is based in San Diego, California.

Headquarters Location

3210 Merryfield Row

San Diego, California, 92121,

United States


Missing: Degron Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Degron Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Degron Therapeutics News

07:45 EDT Degron Therapeutics Co-Founder Provides New Strategy for Molecular Glue in Tumor Immunotherapy

Jun 27, 2022

News provided by Share this article Research published in Cell Chemical Biology showed lenalidomide can enhance cancer-treating ability of PD-1 antibody SAN DIEGO and SHANGHAI, June 27, 2022 /PRNewswire/ -- Degron Therapeutics ("Degron"), a biotechnology company developing a new class of small-molecule medicines that target previously undruggable targets, today announced research suggesting lenalidomide, a molecular glue degrader of IKZF1 and IKZF3, can enhance the potential of the programmed cell death protein 1 (PD-1) antibody to treat cancer. The research was led by Yong Cang, Ph.D., Degron's co-founder and chief scientific officer, and conducted by Dr. Cang's research group at ShanghaiTech University's School of Life Science and Technology. Published in the journal Cell Chemical Biology, the study, "Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling," found that the molecular glue drug lenalidomide could restore the tumor immunotherapy effect of the PD-1 antibody and inhibit tumor growth in mice lacking T-cell co-stimulatory signals. PD-1 is a checkpoint protein on T cells. It normally operates as a type of 'off switch' that helps keep T cells from attacking other cells in the body. "Science-based innovation is core to Degron's exploration into the mechanisms of molecular glue drugs and cancer immunity. The work performed in Dr. Cang's lab reveals that degradation of IKZF1 and IKZF3, can reinvigorate T cells to attack cancers by modulating immune regulatory networks," said Lily Zou, Ph.D., co-founder and CEO of Degron. "This discovery provides new ideas for Degron to dial in such activities into our molecular glue programs when appropriate." "Degron's pipeline of molecular glue degraders against novel oncology targets can be chemically modified to selectively retain the ability to degrade IKZF1 and IKZF3. As a result, such drugs can kill cancer cells by two different mechanisms, directly inactivating oncogenesis and by inducing T cells to target the cancer cells," said Dr. Cang. Dr. Cang's group constructed a humanized mouse model of cereblon (CRBN) that is sensitive to lenalidomide and proved that lenalidomide can co-stimulate CD8+ T cells in the absence of CD28 receptors. Using CD28-KO CRBN humanized mouse models and tumor samples from colorectal cancer patients, the researchers demonstrated that lenalidomide could restore the response of CD28-CD8+ T cells to PD-1 antibodies, thereby enabling the recovery of PD-1 antibody therapy failure due to CD28 deficiency. Dr. Cang's team demonstrated that lenalidomide could co-stimulate T cells by upregulating the secretion of the immune system signaling molecule, interleukin-2 (IL2). Through transcriptome sequencing, the researchers found that lenalidomide can also upregulate Notch targets. Simultaneously blocking both IL2 and Notch signaling pathways simultaneously limits the co-stimulatory effect of lenalidomide on T cells, rendering the combination therapy of lenalidomide and PD-1 antibody ineffective. Approved for marketing in 2005 as an anti-myeloma drug, lenalidomide kills myeloma cells directly while enhancing T-cell anti-tumor activity to inhibiting tumor growth. Lenalidomide is approved for the treatment of multiple myeloma (MM), deletion 5q myelodysplastic syndrome (MDS), mantle cell lymphoma, and other hematological tumors. In addition, lenalidomide's iterative product, pomalidomide, a third-generation immunomodulatory agent that acts as molecular glue, has also achieved great success as a treatment for relapsed and refractory MM. The research was mainly supported by the National Natural Science Foundation of China, the Shanghai Science and Technology Commission, and ShanghaiTech University. Link to the original paper abstract:

Degron Therapeutics Frequently Asked Questions (FAQ)

  • When was Degron Therapeutics founded?

    Degron Therapeutics was founded in 2021.

  • Where is Degron Therapeutics's headquarters?

    Degron Therapeutics's headquarters is located at 3210 Merryfield Row, San Diego.

  • What is Degron Therapeutics's latest funding round?

    Degron Therapeutics's latest funding round is Series A.

  • How much did Degron Therapeutics raise?

    Degron Therapeutics raised a total of $22M.

  • Who are the investors of Degron Therapeutics?

    Investors of Degron Therapeutics include Cowin Venture, bioVENTURE, Med-Fine Capital, Baidu Ventures, DYEE Capital and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.